Therapeutic area
Pain and anesthesia
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
12
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
37
Industry-sponsored
Recruiting Phase 3
30
Industry-sponsored
Recruiting Phase 4 (post-approval)
4
Industry-sponsored
Recent approvals
- Cypsedo (Cipepofol) · Haisco NovelMay 29, 2026
To induce general anesthesia in adults undergoing surgery
- Bondlido (Lidocaine) · Medrx USA Sep 24, 2025
- Vyscoxa (Celecoxib) · Carwin Pharm Assoc Jul 29, 2025
- Xifyrm (Meloxicam) · Azurity Jun 5, 2025
- Qamzova (Meloxicam) · Nanjing Delova Apr 22, 2025
- Symbravo (Meloxicam, Rizatriptan Benzoate) · Axsome Jan 30, 2025
- Journavx (Suzetrigine) · Vertex Pharms INC NovelBreakthrough therapyPriority reviewJan 30, 2025
To treat moderate to severe acute pain
- Letybo (Letibotulinumtoxina-Wlbg) · Hugel INC NovelFeb 29, 2024
To temporarily improve the appearance of moderate-to-severe glabellar lines
- Coxanto (Oxaprozin) · Solubiomix Oct 20, 2023
- Combogesic Iv (Acetaminophen, Ibuprofen Sodium) · Hikma Oct 17, 2023
- Brixadi (Buprenorphine) · Braeburn Priority reviewMay 23, 2023
- Combogesic (Acetaminophen, Ibuprofen) · Aft Pharms US Mar 1, 2023
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HL-1186Phase 36 trials
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Postoperative Pain, Moderate to Severe Acute Postoperative Pain, Postherpetic Neuralgia ( PHN )
- CebranopadolTRN-228Phase 34 trials
Adneuris Therapeutics, Inc. · Pain, Acute Pain, Chronic Pain
- EtoricoxibPhase 34 trials
Laboratorios Silanes S.A. de C.V. · Gout Arthritis, Gout Attack, Acute Low-back Pain
- MaltodextrinPhase 34 trials
RDC Clinical Pty Ltd · Muscle Pain, Chronic Inflammation, Mobility
- CPL-01local anaesthetic of CPL-01, Local anesthetic of CPL-01Phase 33 trials
Cali Pharmaceuticals LLC · Bunion, Postoperative Pain, Hernia, Inguinal
- HRS-2129Phase 33 trials
Shandong Suncadia Medicine Co., Ltd. · Acute Gouty Arthritis, Postoperative Analgesia, Postoperative Pain in Orthopaedics
- MaolactinPhase 33 trials
RDC Clinical Pty Ltd · Muscle Pain, Chronic Inflammation, Mobility
- Active Comparator: MorphinePhase 32 trials
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Pain
- DIPYRONEPhase 32 trials
EMS · Moderate Pain, Severe Pain, Common Cold/Flu
- Etoricoxib fixed doseEtoriPhase 32 trials
Laboratorios Silanes S.A. de C.V. · Gout Arthritis, Gout Attack, Acute Low-back Pain
- HSK21542Phase 32 trials
Haisco Pharmaceutical Group Co., Ltd. · Postoperative Pain Management
- matched to PregabalinPhase 32 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain
- matched to SUZPhase 32 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain
- NeridronatePhase 32 trials
Ambros Therapeutics, Inc. · Complex Regional Pain Syndrome Type I
Largest recruiting Phase 3 trials
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06628908 · 1,100 participants (planned) · Start Oct 1, 2024 · Primary completion May 31, 2027
Drug: Suzetrigine; Placebo (matched to SUZ) and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Anniston, Alabama; Birmingham, Alabama; Daphne, Alabama · 76 sites in all
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisPivotal-lookingRecruiting
Sumitomo Pharma Switzerland GmbHIndustry
NCT05862272 · 1,000 participants (planned) · Start Aug 14, 2023 · Primary completion Jul 2029
Drug: Relugolix Combination Tablet · For: Uterine Fibroids; Endometriosis
Sites: Mobile, Alabama; Chandler, Arizona; Mesa, Arizona · 120 sites in all
- Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07353931 · 900 participants (planned) · Start Feb 9, 2026 · Primary completion Mar 2028
Drug: Eloralintide; Placebo · For: Osteoarthritis; Overweight or Obesity
Sites: Mobile, Alabama; Mesa, Arizona; Phoenix, Arizona · 147 sites in all
- Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral RadiculopathyPivotal-lookingRecruiting
Vertanical GmbHIndustry
NCT06956014 · 810 participants (planned) · Start Sep 22, 2026 · Primary completion Sep 2028
Drug: VER-01 · For: Lumbosacral Radiculopathy
Sites: Mobile, Alabama; Tempe, Arizona; Long Beach, California · 40 sites in all
- Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable AnginaPivotal-lookingRecruiting
Tasly Pharmaceuticals, Inc.Industry
NCT03789552 · 765 participants (planned) · Start Aug 1, 2019 · Primary completion Dec 2026
Drug: T89 capsule; Placebo capsule · For: Chronic Stable Angina Pectoris
Sites: Naples, Florida
- A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07915609 · 756 participants (planned) · Start Oct 26, 2026 · Primary completion Aug 21, 2028
Drug: Berobenatide; Placebo · For: Obesity; Overweight and/or Obesity; Knee Osteoarthritis and 1 more
Sites: Birmingham, Alabama; Tucson, Arizona; Miami, Florida · 4 sites in all
- Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07231419 · 734 participants (planned) · Start Nov 21, 2025 · Primary completion Apr 6, 2027
Drug: Suzetrigine; Placebo (matched to SUZ) · For: Diabetic Peripheral Neuropathic Pain
Sites: Birmingham, Alabama; Mobile, Alabama; Glendale, Arizona · 75 sites in all
- A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07919678 · 656 participants (planned) · Start Oct 26, 2026 · Primary completion Aug 22, 2028
Drug: Berobenatide · For: Obesity; Overweight; Osteoarthritis of the Knee
Sites: Tempe, Arizona; Escondido, California; Rancho Cucamonga, California · 40 sites in all
- Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated PainPivotal-lookingRecruiting
Hope Medicine (Nanjing) Co., LtdIndustry
NCT07318688 · 540 participants (planned) · Start Jan 29, 2026 · Primary completion Mar 1, 2028
Drug: HMI-115; Placebo · For: Endometriosis
Sites: Beijing, China; Nanning, China; Suzhu, China · 5 sites in all
- A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07481630 · 400 participants (planned) · Start Apr 13, 2026 · Primary completion Aug 14, 2028
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111 ) · For: Obesity; Knee Osteoarthritis (OA)
Sites: Phoenix, Arizona; Walnut Creek, California; Hamden, Connecticut · 82 sites in all
More: Pain and anesthesia news · literature
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.